Published on
August 13, 2026
- 13:49 GMT
Antelope Announces Phase 1/2 First-in-Human Study of Investigational Fluorescent Imaging Agent in Prostate Cancer
Enrollment and dosing underway in study of investigational PSMA-targeted fluorescent agent for prostate cancer. NEW YORK, NY, UNITED STATES, August 13, 2026 /EINPresswire.com/ -- Antelope, a clinical-stage biotechnology company developing targeted …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
